BLPH Bellerophon Therapeutics Inc.

12.29
+2.05  (+20%)
Previous Close 10.24
Open 9.75
Price To Book 8.14
Market Cap 59,697,360
Shares 4,857,393
Volume 665,951
Short Ratio
Av. Daily Volume 1,098,918
Stock charts supplied by TradingView

NewsSee all news

  1. Bellerophon Provides Clinical Program Update and Reports Fourth Quarter and Full-Year 2019 Financial Results

    WARREN, N.J., April 06, 2020 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (NASDAQ:BLPH), a clinical-stage biotherapeutics company focused on developing treatments for cardiopulmonary diseases, today provided a

  2. Bellerophon Announces Closing of $15.3 Million Registered Direct Offering of Common Stock

    WARREN, N.J., April 01, 2020 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (NASDAQ:BLPH) ("Bellerophon" or the "Company"), a clinical-stage biotherapeutics company, closed its previously announced registered

  3. Bellerophon Therapeutics to Host Investor Call and Webcast Today on INOpulse® for the Treatment of COVID-19

    WARREN, N.J., March 31, 2020 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (NASDAQ:BLPH), a clinical-stage biotherapeutics company focused on developing treatments for cardiopulmonary diseases, announced that it

  4. Bellerophon Announces $15.3 Million Registered Direct Offering Priced At-the-Market

    WARREN, N.J., March 30, 2020 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (NASDAQ:BLPH) ("Bellerophon" or the "Company"), a clinical-stage biotherapeutics company, today announced that it has entered into

  5. Bellerophon Therapeutics Announces First Patient Treated with INOpulse® Inhaled Nitric Oxide Therapy for COVID-19

    WARREN, N.J., March 30, 2020 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (NASDAQ:BLPH), a clinical-stage biotherapeutics company focused on developing treatments for cardiopulmonary diseases, today announced

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Pivotal cohort 3 (Phase 3) initiation due 1Q 2020.
INOpulse delivery device
Pulmonary Hypertension associated with Interstitial Lung Disease (PH-ILD)
Phase 3 trial stopped due to futility - August 7, 2018.
INOpulse delivery device
Pulmonary Arterial Hypertension (PAH)
Phase 2b trial planned.
INOpulse delivery device
Pulmonary Hypertension associated with COPD (PH-COPD)
Phase 2 data noted statistically and clinically significant improvements in hemodynamic parameters - February 18, 2020.
INOpulse delivery device
Pulmonary hypertension associated with Pulmonary Fibrosis or Sarcoidosis (PH-Sarcoidosis)

Latest News

  1. Bellerophon Provides Clinical Program Update and Reports Fourth Quarter and Full-Year 2019 Financial Results

    WARREN, N.J., April 06, 2020 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (NASDAQ:BLPH), a clinical-stage biotherapeutics company focused on developing treatments for cardiopulmonary diseases, today provided a

  2. Bellerophon Announces Closing of $15.3 Million Registered Direct Offering of Common Stock

    WARREN, N.J., April 01, 2020 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (NASDAQ:BLPH) ("Bellerophon" or the "Company"), a clinical-stage biotherapeutics company, closed its previously announced registered

  3. Bellerophon Therapeutics to Host Investor Call and Webcast Today on INOpulse® for the Treatment of COVID-19

    WARREN, N.J., March 31, 2020 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (NASDAQ:BLPH), a clinical-stage biotherapeutics company focused on developing treatments for cardiopulmonary diseases, announced that it

  4. Bellerophon Announces $15.3 Million Registered Direct Offering Priced At-the-Market

    WARREN, N.J., March 30, 2020 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (NASDAQ:BLPH) ("Bellerophon" or the "Company"), a clinical-stage biotherapeutics company, today announced that it has entered into

  5. Bellerophon Therapeutics Announces First Patient Treated with INOpulse® Inhaled Nitric Oxide Therapy for COVID-19

    WARREN, N.J., March 30, 2020 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (NASDAQ:BLPH), a clinical-stage biotherapeutics company focused on developing treatments for cardiopulmonary diseases, today announced

  6. FDA Grants Bellerophon Emergency Expanded Access for INOpulse® for the Treatment of COVID-19 Virus

    WARREN, N.J., March 20, 2020 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (NASDAQ:BLPH) ("Bellerophon" or the "Company"), a clinical-stage biotherapeutics company, today announced that the U.S. Food and Drug

  7. Bellerophon Announces Agreement with the FDA on its Planned Pivotal Phase 3 Study for the Treatment of Pulmonary Hypertension Associated with Pulmonary Fibrosis

    WARREN, N.J., March 10, 2020 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (NASDAQ:BLPH) ("Bellerophon" or the "Company"), a clinical-stage biotherapeutics company, today announced the successful completion of its

  8. Bellerophon Reports Positive Top-Line Data from an Ancillary Acute Hemodynamic Study of INOpulse® for Treatment of Pulmonary Hypertension Associated with Pulmonary Fibrosis

    WARREN, N.J., Feb. 18, 2020 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (NASDAQ:BLPH) ("Bellerophon" or the "Company"), a clinical-stage biotherapeutics company, today announced positive top-line data from a

  9. Bellerophon Announces 1-for-15 Reverse Stock Split

    WARREN, N.J., Feb. 07, 2020 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (NASDAQ:BLPH) ("Bellerophon" or the "Company"), a clinical-stage biotherapeutics company, today announced the filing of a certificate of

  10. Bellerophon Announces Positive Top-line Results from Cohort 2 of Phase 2/3 Study of INOpulse® for Treatment of Pulmonary Hypertension Associated with Interstitial Lung Disease

    Statistically Significant Improvement Demonstrated in Moderate to Vigorous Physical Activity Bellerophon Intends to Initiate Pivotal Phase 3 in First Quarter of 2020 Company Enters Into $10M Convertible Financing

  11. Bellerophon Announces Positive Initial Data from Acute Hemodynamic Dose Escalation Study of INOpulse® for Treatment of Pulmonary Hypertension Associated with Interstitial Lung Disease

    WARREN, N.J., Nov. 12, 2019 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (NASDAQ:BLPH) ("Bellerophon" or the "Company"), a clinical-stage biotherapeutics company, today announced positive initial data from an

  12. Bellerophon Presents New Data from Cohort 1 of Ongoing Phase 2/3 Study of INOpulse® for Treatment of Pulmonary Hypertension Associated with Interstitial Lung Disease at Pulmonary Fibrosis Foundation Summit 2019

    WARREN, N.J., Nov. 07, 2019 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (NASDAQ:BLPH) ("Bellerophon" or the "Company"), a clinical-stage biotherapeutics company, is presenting data from Cohort 1 of its ongoing

  13. Bellerophon Provides Business Update and Reports Third Quarter 2019 Financial Results

    WARREN, N.J., Nov. 06, 2019 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (NASDAQ:BLPH) ("Bellerophon" or the "Company"), a clinical-stage biotherapeutics company, today provided a business update and reported

  14. Bellerophon Presents New Positive Data from Cohort 1 of Ongoing Phase 2/3 Study of INOpulse® for Treatment of Pulmonary Hypertension Associated with Interstitial Lung Disease at CHEST 2019 Annual Meeting

    Results Presented in Late-Breaking Abstract as an Oral PresentationPresentation Will Also be Published in the Highlights from CHEST Special Edition WARREN, N.J., Oct. 23, 2019 (GLOBE NEWSWIRE) -- Bellerophon

  15. Bellerophon to Present New Data from Cohort 1 of Ongoing Phase 2/3 Study of INOpulse® for Treatment of Pulmonary Hypertension Associated with Interstitial Lung Disease at CHEST 2019 Annual Meeting

    Results to be Presented in Late-Breaking Abstract as an Oral Presentation Presentation Will Also be Published in the Highlights from CHEST Special Edition WARREN, N.J., Oct. 14, 2019 (GLOBE NEWSWIRE) -- Bellerophon

  16. Bellerophon Receives Orphan Drug Designation for Nitric Oxide in the Treatment of Idiopathic Pulmonary Fibrosis

    WARREN, N.J., Sept. 16, 2019 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (NASDAQ:BLPH) ("Bellerophon" or the "Company"), a clinical-stage biotherapeutics company, announced today the U.S. Food and Drug

  17. Bellerophon to Present at the H.C. Wainwright 21st Annual Global Investment Conference

    WARREN, N.J., Sept. 04, 2019 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (NASDAQ:BLPH) ("Bellerophon" or the "Company"), a clinical-stage biotherapeutics company, announced today that Fabian Tenenbaum, Chief